Lb Pharmaceuticals (LBRX) Net Income towards Common Stockholders (2024 - 2026)

Lb Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 259.1% year-over-year to -$19.1 million in Q1 2026; TTM through Mar 2026 was -$14.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25205.0, up 60.06% from the prior year.
• Net Income towards Common Stockholders slipped to -$19.1 million in Q1 2026 per LBRX's latest filing, from $13.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $58.0 million in Q4 2024 and bottomed at -$19.1 million in Q1 2026.
• The 3-year median for Net Income towards Common Stockholders is -$4.4 million (2025), against an average of $4.9 million.
• Across the five-year window, Net Income towards Common Stockholders soared 74.92% in 2025 and slumped 259.1% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $58.0 million in 2024, then sank by 76.35% to $13.7 million in 2025, then tumbled by 239.0% to -$19.1 million in 2026.
• Per Business Quant, the three latest LBRX Net Income towards Common Stockholders figures stand at -$19.1 million (Q1 2026), $13.7 million (Q4 2025), and -$3.6 million (Q3 2025).